查詢結果分析
相關文獻
- Use of Tumor Necrosis Factor-α Antagonists in Patients with Concurrent Rheumatoid Arthritis or Spondyloarthritis and Hepatitis B
- Estimated Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Rheumatic Diseases Treated with Tumor Necrosis Factor Blockers
- Clinical Disease Pattern and Drug Evaluation of Patients with Seronegative Spondyloarthritis at the Outpatient Department
- 僵直性脊椎炎及軸心型脊椎關節炎診斷之進展
- Extra-articular Manifestations of Ankylosing Spondylitis: A Single Medical Center Experience in Taiwan
- 慢性B型肝炎之治療
- Fas and CD45RO Antigen Expression on Peripheral Blood Mononuclear Cells in Patients with Ankylosing Spondylitis: A Comparison with Autoimmune Diseases
- Immunogenicity and Reactogenicity of Two Recombinant Hepatitis B Vaccines in Healthy Adolescents on Two-dose Schedule
- B型肝炎帶原的中醫療法
- 僵直性脊椎炎病案二例
頁籤選單縮合
題 名 | Use of Tumor Necrosis Factor-α Antagonists in Patients with Concurrent Rheumatoid Arthritis or Spondyloarthritis and Hepatitis B=抗腫瘤壞死因子藥物在慢性肝炎合併風濕病患者之使用 |
---|---|
作 者 | 吳政翰; 梁培英; 陳佳音; 黃駿煌; 蔡敏鈴; 陳依伶; 楊凱介; 程兆明; 王世叡; 蔡嘉哲; 陳培哲; 魏正宗; | 書刊名 | 中華民國風濕病雜誌 |
卷 期 | 25:1/2 2011.12[民100.12] |
頁 次 | 頁35-40 |
分類號 | 418.29 |
關鍵詞 | 抗腫瘤壞死因子藥物; B型肝炎; 僵直性脊椎炎; 脊椎關節炎; TNF-α blockade; Hepatitis B; Rheumatoid arthritis; Ankylosing spondylitis; Spondyloarthritis; |
語 文 | 英文(English) |
中文摘要 | 目的:研究生物製劑治療風濕病在B型肝炎病人的安全性。方法:回溯性地研究自西元2002年1月至2010年9月間使用恩博或復邁的風濕病人,分析病人肝功能及病毒量判斷是否有B型肝炎再活動。結果:161個使用恩博或復邁的風濕病人中,有17人B肝表面抗原陽性且皆未使用預防性抗病毒治療,排除其中9人無治療前病毒量以致無法判斷治療後是否有B型肝炎再活動,我們分析其餘8個病人之中只有1人(12.5%)在治療後4個月疑有B型肝炎再活動,在沒有使用抗病毒藥且繼續使用生物製劑的情況下,病人的肝功能自行回到正常值。結論:所有病人在使用生物製劑之前都需檢測B型肝炎,並於療程期間定期追蹤肝功能,若有B型肝炎再活動證據,應使用抗病毒藥治療,然而預防性的抗病毒治療未必是需要的。 |
英文摘要 | Objective: To assess the safety of biological agents in patients with rheumatic diseases associated with hepatitis B in one medical center. Methods: Patients who had taken etanercept or adalimumab from January 2002 to September 2010 in Chung Shan Medical University Hospital were reviewed in the study. We retrospectively investigated a series of serum aminotransferase (ALT) levels, hepatitis serologic status including HBV surface antigen (HBsAg), HBV surface antibody (HBsAb), HBV core IgG Ab (HBcAb), and HBV-DNA. Endpoints were clinical reactivation and subclinical reactivation as defined by ALT and viral load, respectively. Results: A total of 161 patients were documented to have taken etanercept or adalimumab. Among the 161 patients, 17 (10.56%) patients had chronic hepatitis B (HbsAg+) without anti-viral agent prophylaxis prior to biologics. Nine patients were excluded from the analysis due to missing data. Of these remaining 8 patients, only 1 (12.5%) patient had transient mild clinical reactivation after taking etanercept for 4 months. Spontaneous remission of this patient’s HBV reactivation was noted without anti-viral therapy. Conclusion: All rheumatic patients who plan to take biologics treatment should undergo tests for HBV, and they should have a close follow-up with ALT during therapy. Preemptive anti-viral therapy is commenced in patients who develop evidence of disease reactivation. For chronic hepatitis patients, it might not be necessary to use a prophylactic anti-viral agent prior to biologics. |
本系統中英文摘要資訊取自各篇刊載內容。